These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Therapeutic agents for disorders of bone and calcium metabolism--Teriparatide, parathyroid hormone (1-34) as a daily subcutaneous injection].
    Author: Hashimoto Y, Wakayama N, Miyauchi A.
    Journal: Clin Calcium; 2007 Jan; 17(1):48-55. PubMed ID: 17211093.
    Abstract:
    Teriparatide is the recombinant N-terminal fragment (1-34) of endogenous human parathyroid hormone (PTH) and has been approved and used in many countries including the United States and Europe. Treatment with teriparatide 20 microg/day for 18 months increased spine bone mineral density (BMD) by approximately 10% and reduced the incidence of vertebral fractures by 65% and nonvertebral fragility fractures by 53%. Furthermore, the results from paired-biopsy showed that the treatment with teriparatide improved bone architecture. Teriparatide is being developed in Japan as a treatment for osteoporosis.
    [Abstract] [Full Text] [Related] [New Search]